(NYSE: SER) Takes The Top Spot On Tuesday's Watchlist (Low Float Idea With Bullish Technicals)

A biopharma company just caught my attention.

*Sponsored (NYSE: SER) Takes The Top Spot On Tuesday's Watchlist (Low Float Idea With Bullish Technicals) July 28th Greetings Readers, A biopharma company just caught my attention. Advancing innovative therapies aimed at addressing challenging neurological conditions, this NYSE American profile is currently flying under-the-radar. For how long? That's a great question. With a focus on next-generation molecules, including cann-a-binoids, their work spans diverse central nervous system disorders and beyond. Collaborations with specialized partners support the exploration of novel RNA-based medicines targeting vaccine immunology, cancer immunotherapy, and gene therapy. This forward-thinking approach to drug discovery highlights a commitment to unlocking new possibilities in medicine, making the company well worth closer attention for those interested in emerging therapeutic frontiers. Mix in a low float of fewer than 3Mn shares (meaning volatility potential could be high), a couple of significant analyst targets, a slew of bullish technicals, and recent PR highlights suggesting a company making transformative moves, and there's little doubt why this biopharma idea has hit my radar. Take a moment to consider pulling up this NYSE American idea: Serina Therapeutics, Inc. (NYSE: SER) Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). And based on several potential catalysts, (NYSE: SER) has my immediate attention and top watchlist spot. Take a look: #1. A Low Float Could Create An Environment For Heightened Volatility. #2. A Pile Of Bullish Technical Indicators May Suggest A Developing Trend Worth Watching Closely. #3. Serina Provides Business Update Of Recent Company Highlights Signaling Critical Movements Being Made. #4. Two Analyst Targets Imply That SER May Be Significantly Undervalued From Current Chart Levels. But more on those in a second... A Next-Gen Polymer Therapeutic Serina Therapeutics' proprietary POZ platform is built on a synthetic, water-soluble, low-viscosity polymer known as poly (2-oxazoline). During the synthesis process, a precise amount of drug is incorporated onto the polymer backbone using pendant alkyne groups and metal-catalyzed “click chemistry.” This POZ technology enables enhanced control over drug loading and allows for more precise management of drug release rates. As a result, drugs with narrow therapeutic windows can be engineered to maintain more desirable and stable blood concentrations. While optimized for small molecules, the platform is also applicable to proteins, aptamers, and other classes of molecules. POZ Delivers Key Advantages POZ is engineered to address the limitations of PEG (polyethylene glycol) and other biocompatible polymers – such as immunogenicity, where unlike PEG, POZ does not elicit an immune response or stimulate development of antibodies to the polymer itself. Enabling Continuous Drug Delivery And Why It Matters Many drugs, for example those used to treat neurological disorders like Parkinson’s, have narrow therapeutic ranges in which they can work safely and efficaciously. They are often dosed more frequently – resulting in large and frequent fluctuations in drug exposure. They have to be monitored and dose adjusted with greater frequency, and on an individual basis. These fluctuations present clinical, compliance and quality of life challenges for many patients. Administered Subcutaneously, POZ Provides Extended Delivery Enabled by POZ Serina Therapeutics is developing proprietary drugs to treat neurological diseases. Its lead product candidate, SER-252 for advanced Parkinson’s disease, is expected to enter clinical trials in 2025. Current discovery and development efforts include a focus on unlocking the potential of cann-a-binoids and other molecules across a range of CNS indications and beyond. The company’s POZ platform partners are at the forefront of advancing novel RNA medicines in vaccine immunology, cancer immunotherapy, and gene therapy. Grab Sources Here: SER Website. SER Presentation. ----- (NYSE: SER) - These 4 Potential Catalysts Have Gained Our Attention! #1. SER Potential Catalyst - A Low Float Could Create An Environment For Heightened Volatility. According to info from the Yahoo Finance website, SER has a fairly low float. The website reports this profile to have roughly 2.79Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. ----- #2. SER Potential Catalyst - A Pile Of Bullish Technical Indicators May Suggest A Developing Trend Worth Watching Closely. On Monday at 4:00PM EST, Barchart was reporting several triggered technical indicators across the short, medium, and long term for SER. Here's their list (as of 4:00PM EST Monday): Short Term Indicators 20 Day Moving Average 20 - 100 Day MA Crossover 20 - 200 Day MA Crossover Medium Term Indicators 50 - 100 Day MA Crossover 50 - 150 Day MA Crossover 50 - 200 Day MA Crossover Long Term Indicators 100 Day Moving Average 150 Day Moving Average 200 Day Moving Average 100 - 200 Day MA Crossover Make sure to watch these technical indicators closely moving forward. ----- #3. SER Potential Catalyst - Serina Provides Business Update Of Recent Company Highlights Signaling Critical Movements Being Made. Recently, SER shared a PR filled with recent attention-catching highlights. Check out some of the key developments: Secured Funding: Serina secured $15Mn in equity financing since late 2024, including a $10Mn two-tranche in-vest-ment from JuvVentures (closed in January 2025) and a $5Mn private placement in April 2025 from a Securities Purchase Agreement entered with certain board directors and investors. This financial foundation enhances Serina's ability to focus on advancing its core therapeutic programs as the company prepares to initiate a Phase 1b trial of SER-252 in Q4 2025. New Board Directors Appointed: Serina added experienced biotech leaders Karen J. Wilson and Dr. Jay Venkatesan to the Board of Directors during the quarter, adding deep collective experience in corporate strategy, business development, and capital markets. Presented New POZ Platform Data: Shared data at the 4th LNP Formulation & Process Development Summit 2025 demonstrating that Serina’s POZ-lipid, a key component of lipid nanoparticles (LNPs), did not trigger an IgM or IgG antibody response following repeat dosing in rats in a vaccine format. In contrast, polyethylene glycol (PEG)-lipid standards, commonly used in current LNP formulations, elicited a strong and boosted antibody response. The absence of an immune response to Serina’s POZ-lipid represents a novel discovery that could enable the development of safer and more effective LNP formulations for gene therapy and RNA-based medicines. ----- #4. SER Potential Catalyst - Two Analyst Targets Imply That SER May Be Significantly Undervalued From Current Chart Levels. TipRanks is sharing at least two analyst targets for SER: From Monday's closing valuation, these targets are providing potential upside of over 150% and over 85%, respectively. Could SER be undervalued from current chart levels? ----- The (NYSE: SER) Recap - 4 Potential Catalysts Lead The Way #1. A Low Float Could Create An Environment For Heightened Volatility. #2. A Pile Of Bullish Technical Indicators May Suggest A Developing Trend Worth Watching Closely. #3. Serina Provides Business Update Of Recent Company Highlights Signaling Critical Movements Being Made. #4. Two Analyst Targets Imply That SER May Be Significantly Undervalued From Current Chart Levels. ----- Coverage is officially kicked off on Serina Therapeutics, Inc. (NYSE American: SER). Be on the lookout for updates coming soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 07/28/2025 and ending on 07/29/2025 to publicly disseminate information about (SER:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (SER:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/ser-vkxoo/#details

SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 US Unsubscribe | Update Profile | Constant Contact Data Notice